Intracavitary chromic phosphate (32P) colloidal suspension therapy.
Two-hundred-eighty-nine patients received treatment with chronic phosphate (32P) colloidal suspension (CPCS) 346 times since 1963. One-hundred-seventy-eight patients received 200 intraperitoneal treatments. One-hundred-fifteen patients received 144 intrapleural treatments. Six patients received both intraperitoneal and intrapleural treatments. Two patients received two intrapericardial treatments. Results of therapy were evaluated three months later and then at yearly intervals. In those patients who survived three months, the referring physician observed improvement in 85% of intraperitoneal treatment and in 75% of intrapleural treatments.
D001918:Brachytherapy; D002857:Chromium / Q000627:therapeutic use*; D017608:Chromium Compounds; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000532:radiotherapy*; D010532:Peritoneal Diseases / Q000150:complications / Q000532:radiotherapy; D010537:Peritoneum; D010710:Phosphates / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D010994:Pleura; D010996:Pleural Effusion / Q000150:complications / Q000532:radiotherapy
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate